This study, led by Dr. Carl Ola Landgren, explores multiple myeloma patients' perceptions of MRD negativity, including its significance for treatment success, access to novel therapies, and its role in clinical trial endpoints.

For any questions or concerns regarding the study, participants can contact HealthTree Patient Navigators at support@healthtree.org.